Full Text
Secukinumab Significantly Reduces Work Impairment and Indirect Costs Compared To Ustekinumab and Etanercept In The United Kingdom

Abstract

Authors

R Warren A Halliday CN Graham I Gilloteau L Miles B Sherif D McBride

Back to Volume 20, Issue 9
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×